Yes, a cure for sickle cell disease is no longer only on the horizon. For some patients it is already here. A bone marrow (stem cell) transplant from a matched donor can cure the disease, and since late 2023 two gene therapies built from a patient’s own stem cells have been approved in the United States. The catch is that these treatments are intensive, expensive, and not yet suitable or available for most people living with the condition. The rest of the story is about closing that gap.
Progress in haematology and genetic research over the past few decades has changed what we can offer. Below I walk through where the disease comes from, the treatments that control it, the ones that can cure it, and the honest trade-offs patients and families should weigh.
Why Sickle Cell Disease Is a Target for a Cure
Sickle cell disease (SCD) is an inherited disorder of hemoglobin, the oxygen-carrying protein inside red blood cells. It is caused by a single change in the HBB gene, which makes the beta-globin chain of hemoglobin. That change produces hemoglobin S (HbS), which clumps into stiff polymers when oxygen levels fall.
Red cells packed with polymerized HbS become rigid and curved. They block small blood vessels, break apart early, and trigger inflammation. The result is anemia, sudden pain crises, and gradual damage to organs such as the brain, lungs, kidneys, and spleen.
Because the whole disease traces back to one gene expressed in one cell line, it is an ideal candidate for a cure. Replace or correct the blood-forming stem cells in the bone marrow, and every red cell they make afterward can be healthy. If you want the genetics in more depth, see our explainer on the cause of sickle cell disease and how it affects long-term outlook.
Who Is at Risk
A child develops SCD by inheriting two abnormal beta-globin genes, at least one of which is the sickle gene. Carrying one sickle gene alongside a normal one is called sickle cell trait, which usually causes no symptoms. The sickle gene is most common in people of African, Mediterranean, Middle Eastern, and Indian ancestry, and a family history is the main risk factor for sickle cell disease.
Standard Treatments That Control the Disease
Before discussing cures, it helps to know the treatments most patients rely on day to day. These do not remove the disease, but they reduce complications and have greatly improved survival.
- Hydroxyurea: an oral medicine that raises fetal hemoglobin (HbF), a form of hemoglobin that does not sickle. It reduces pain crises, acute chest syndrome, and the need for transfusion, and it remains the backbone of care.
- Blood transfusions: used for severe anemia, acute chest syndrome, and stroke prevention. Regular transfusion requires monitoring for iron overload, often with iron-chelating medicines.
- L-glutamine: an oral amino acid powder approved to reduce pain crises, thought to work by lowering oxidative stress in red cells.
- Crizanlizumab: an intravenous antibody that blocks P-selectin, a molecule that helps sickled cells stick to vessel walls.
- Pain management and prevention: hydration, prompt treatment of crises with anti-inflammatory drugs and opioids when needed, vaccinations, and penicillin prophylaxis in young children.
One update to older articles on this topic: voxelotor, a drug designed to stop HbS from polymerizing, was withdrawn from the market by its manufacturer in 2024 over safety concerns. Anyone still holding a supply should speak with their hematologist.
Treatments That Can Cure Sickle Cell Disease Today
There are now three broad routes to a cure. All of them work by giving the patient a new population of blood-forming stem cells that no longer make sickling red cells.
| Approach | Source of stem cells | How it works | Main limitations |
|---|---|---|---|
| Matched sibling transplant | Healthy brother or sister with matching tissue type | Donor marrow replaces the patient’s marrow | Few patients have a matched sibling; risk of graft-versus-host disease |
| Alternative donor transplant (e.g. haploidentical) | Half-matched relative or unrelated donor | Widens the donor pool using newer transplant techniques | Higher risk of graft failure and complications; mostly in specialist centers |
| Gene editing (exa-cel) | Patient’s own stem cells | CRISPR switches fetal hemoglobin production back on | Requires high-dose chemotherapy; very high cost; limited centers |
| Gene addition (lovo-cel) | Patient’s own stem cells | A virus vector adds a modified, anti-sickling beta-globin gene | Requires high-dose chemotherapy; boxed warning for blood cancer; very high cost |
Stem Cell Transplant
Transplant from an HLA-matched sibling is the longest-established cure and has the most follow-up data. It is usually considered for children and young adults with severe disease. The main barriers are finding a donor and the risks of the procedure itself, including infection, infertility from conditioning chemotherapy, and graft-versus-host disease.
Gene Therapy
In December 2023 the US FDA approved two gene therapies for people aged 12 and older who have recurrent pain crises. Exagamglogene autotemcel (exa-cel) uses CRISPR/Cas9 gene editing to disable a switch called BCL11A, allowing the cells to make fetal hemoglobin again. Lovotibeglogene autotemcel (lovo-cel) uses a lentiviral vector to add a working, anti-sickling beta-globin gene.
Because the patient is their own donor, there is no need for a match and no risk of graft-versus-host disease. That is the major step forward.
What Gene Therapy Actually Involves
Patients are sometimes surprised by how demanding the process is. In my practice I walk families through each stage before they commit.
- Preparation: several months of regular transfusions to lower HbS levels before stem cells are collected.
- Stem cell collection: the stem cells are mobilized into the blood with a drug called plerixafor and collected by apheresis. This may take more than one cycle.
- Manufacturing: the cells are edited or modified in a specialized laboratory, which takes weeks to months.
- Conditioning: high-dose busulfan chemotherapy clears the existing bone marrow. This carries risks including infection, mouth sores, and infertility.
- Infusion and recovery: the modified cells are returned by drip, followed by a hospital stay of several weeks while blood counts recover, then long-term follow-up.
Recent Developments and Future Directions
The next wave of research focuses on making cures safer and more accessible. Key areas include:
- Gentler conditioning: antibody-based approaches that clear marrow space without high-dose chemotherapy, which could reduce infertility and infection risk.
- In vivo gene editing: delivering the editing tools directly into the body, avoiding stem cell collection and laboratory manufacturing altogether.
- Newer editing tools: base editing and prime editing aim to correct the sickle mutation precisely rather than working around it.
- Global access: most people with SCD live in sub-Saharan Africa and India, where current gene therapies are out of reach. Newborn screening, hydroxyurea access, and lower-cost transplant programs remain the most important advances for them.
The hematology community is hopeful, but the aim now is less about proving a cure is possible and more about making it available to everyone who needs it.
Key Takeaways
- Sickle cell disease comes from a single change in the HBB gene, which makes it a strong candidate for a genetic cure.
- Hydroxyurea, transfusions, and newer medicines control the disease but do not cure it.
- Stem cell transplant and two approved gene therapies can cure it, but they involve intensive chemotherapy and are available only at specialist centers.
- Future work aims for gentler, cheaper, and globally accessible cures. Learn more in our sickle cell guide.
Frequently Asked Questions
Is there a cure for sickle cell disease right now?
Yes. A stem cell transplant from a matched donor and the two approved gene therapies can cure sickle cell disease for eligible patients. They are not right for everyone, and each carries serious risks that should be discussed with a specialist team.
Who qualifies for sickle cell gene therapy?
In the United States, the approved gene therapies are for people aged 12 and older with a history of recurrent pain crises. Patients also need to be well enough to tolerate high-dose chemotherapy. A hematologist at a treatment center assesses each case individually.
Does gene therapy affect fertility?
The gene therapy itself does not, but the busulfan chemotherapy used to prepare the marrow can cause infertility. Egg, sperm, or tissue preservation should be discussed before treatment starts.
If I am cured, can I still pass on the sickle gene?
Yes. Gene therapy and transplant change the blood-forming cells, not the eggs or sperm. Children can still inherit the sickle gene, so genetic counseling remains useful for family planning.
